Efficacy and hepatic safety of rilpivirine (RPV, TMC278) in treatment-naïve, HIV-1-infected patients co-infected with hepatitis B and/or C: pooled 96-week analysis of the Phase III ECHO and THRIVE trials

Conference Reports for NATAP

Infectious Disease Societyof America (IDSA)
IDSA 49th Annual Meeting
October 20-23, 2011
Boston, MA


Efficacy and hepatic safety of rilpivirine (RPV, TMC278) in treatment-naïve, HIV-1-infected patients co-infected with hepatitis B and/or C: pooled 96-week analysis of the Phase III ECHO and THRIVE trials

	Reported by Jules Levin IDSA 2011 Oct 20-23 Boston, MA Judith Feinberg,1 Ezio Baraldi,2 Robert Finlayson,3 Hans-Jürgen Stellbrink,4 Edmund Wilkins,5 Simon Vanveggel,6 Marita Stevens,6 Katia Boven7 1University of Cincinnati, Cincinnati, OH, USA; 2TrialTech Clinical Research, Pretoria, South Africa; 3Taylor Square Private Clinic, Sydney, Australia;4ICH Study Center, Hamburg, Germany; 5North Manchester General Hospital, Manchester, UK; 6Tibotec BVBA, Beerse, Belgium; 7Tibotec Inc. Titusville, NJ, USA